Cited 0 times in
Surgical Treatment of Stage III Lung Cancer After Chemotherapy and Radiotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김형중 | - |
dc.contributor.author | 이두연 | - |
dc.date.accessioned | 2023-07-12T00:07:31Z | - |
dc.date.available | 2023-07-12T00:07:31Z | - |
dc.date.issued | 1994-04 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/194883 | - |
dc.description.abstract | We have experienced eight patients with advanced bronchogenic carcinomas who underwent resectional surgery after receiving preoperative adjuvant chemotherapy and radiotherapy during the period March, 1990, to February, 1992. Four patients were in stage IDA and four in stage 1MB, of which six had epidermoid carcinomas and two small cell carcinomas. All patients were male with ages ranging from 48 to 73 (mean 56.7) years. The induction chemotherapy for six patients consisted of cisplatin and VP-16 (Etoposide) only, and two patients were given fluorouracil\cyclophosphamide and cyclophosphamide\adriamycin\cisplatin in addition to cisplati\VP-16, respectively. All patients also received four to six weeks of radiotherapy following chemotherapy and were re-evaluated for the possibility of surgery after four weeks of observation. All patients underwent pneumonectomies. Postoperative histological staging revealed complete responses in two patients, partial responses in three and no response in three. Patients were followed-up for seven to 33 (mean 21.5) months after the diagnosis of lung cancer. Six patients died 1, 2, 3, 10, 14 and 26 months postoperatively and two patients are alive, revealing no evidence of tumor recurrence 24 months postoperatively. Induction therapy may induce a better resectability by the conversion of the lung cancer to a lower clinical stage by the time of surgery. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Oxford University Press | - |
dc.relation.isPartOf | JAPANESE JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / therapeutic use | - |
dc.subject.MESH | Brachytherapy | - |
dc.subject.MESH | Carcinoma, Small Cell / drug therapy | - |
dc.subject.MESH | Carcinoma, Small Cell / pathology | - |
dc.subject.MESH | Carcinoma, Small Cell / radiotherapy | - |
dc.subject.MESH | Carcinoma, Small Cell / surgery* | - |
dc.subject.MESH | Carcinoma, Squamous Cell / drug therapy | - |
dc.subject.MESH | Carcinoma, Squamous Cell / pathology | - |
dc.subject.MESH | Carcinoma, Squamous Cell / radiotherapy | - |
dc.subject.MESH | Carcinoma, Squamous Cell / surgery* | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Cisplatin / administration & dosage | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Cyclophosphamide / administration & dosage | - |
dc.subject.MESH | Doxorubicin / administration & dosage | - |
dc.subject.MESH | Etoposide / administration & dosage | - |
dc.subject.MESH | Fluorouracil / administration & dosage | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Iodine Radioisotopes / therapeutic use | - |
dc.subject.MESH | Lung Neoplasms / drug therapy | - |
dc.subject.MESH | Lung Neoplasms / pathology | - |
dc.subject.MESH | Lung Neoplasms / radiotherapy | - |
dc.subject.MESH | Lung Neoplasms / surgery* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Pneumonectomy | - |
dc.subject.MESH | Radiotherapy Dosage | - |
dc.subject.MESH | Remission Induction | - |
dc.title | Surgical Treatment of Stage III Lung Cancer After Chemotherapy and Radiotherapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Doo Yun Lee | - |
dc.contributor.googleauthor | Hae Kyoon Kim | - |
dc.contributor.googleauthor | Hyo Chae Paik | - |
dc.contributor.googleauthor | Hyung Joong Kim | - |
dc.contributor.googleauthor | Sang Jin Kim | - |
dc.contributor.localId | A01158 | - |
dc.contributor.localId | A02745 | - |
dc.relation.journalcode | J01207 | - |
dc.identifier.eissn | 1465-3621 | - |
dc.identifier.pmid | 8158856 | - |
dc.identifier.url | http://jjco.oxfordjournals.org/content/24/2/101.abstract | - |
dc.contributor.alternativeName | Kim, Hyung Jung | - |
dc.contributor.affiliatedAuthor | 김형중 | - |
dc.contributor.affiliatedAuthor | 이두연 | - |
dc.citation.volume | 24 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 101 | - |
dc.citation.endPage | 105 | - |
dc.identifier.bibliographicCitation | JAPANESE JOURNAL OF CLINICAL ONCOLOGY, Vol.24(2) : 101-105, 1994-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.